Abstract
Purpose
Endometrial mesonephric-like adenocarcinoma (ML-AC) represents a recently recognized subtype of endometrial adenocarcinoma (AC) associated with a subtle immunophenotype with a characteristic KRAS-mutation. Detailed clinico-pathologic analyses and prognostic data on ML-AC are limited.
Methods
We report a series of four cases with histopathological, immunohistochemical, and molecular analyses. These cases as well as the data of previously published cases were reviewed for clinico-pathologic variables and clinical follow-up information.
Results
Forty cases of ML-AC were identified. ML-AC represents about 1% of all endometrial carcinomas. Similar to other types of endometrial AC, vaginal bleeding was the leading presenting symptom, and the mean age was 60.0 years (range 31–91). More than a half of the patients presented with locally advanced disease (≥ FIGO stage II) at time of diagnosis, developed a recurrence or died of the disease within a mean follow-up period of 24.7 months (range 3–144.5 months). The most common site of distant disease was pulmonary involvement. Microscopically, ML-ACs present with mixed morphology and show a co-expression of so-called mesonephric and Müllerian markers, suggesting a Müllerian origin of the tumors. Immunostaining for PD-L1 was negative in all tested cases, using different antibodies against PD-L1. Retained staining for mismatch repair proteins on immunohistochemistry and a POLE-mutation suggest a copy number low phenotype within the molecular classification of endometrial carcinomas. Almost all cases showed a KRAS-mutation at codon 12 (mostly G12V).
Conclusion
Uterine ML-AC represents a distinct subtype of invasive endometrial AC, associated with KRAS-mutations and characteristic immunohistochemical findings. Clinically, ML-AC may show an aggressive behavior with a high rate of recurrent disease and a substantial risk for distant metastatic disease, especially to the lungs.
Similar content being viewed by others
References
Ando H, Watanabe Y, Ogawa M, Tamura H, Deguchi T, Ikeda K, Fujitani M, Shioji M, Tsujie T, Doi R, Wakimoto A, Adachi S (2017) Mesonephric adenocarcinoma of the uterine corpus with intracystic growth completely confined to the myometrium: a case report and literature review. Diagn Pathol 12(1):63
Bagué S, Rodríguez IM, Prat J (2004) Malignant mesonephric tumors of the female genital tract: a clinicopathologic study of 9 cases. Am J Surg Pathol 28(5):601–607
Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, Goodfellow PJ, Pollock PM (2012) FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS ONE ONE 7(2):e30801
Clement PB, Young RH, Keh P, Ostör AG, Scully RE (1995) Malignant mesonephric neoplasms of the uterine cervix. A report of eight cases, including four with a malignant spindle cell component. Am J Surg Pathol 19(10):1158–1171
Corey L, Valente A, Wade K (2019) Personalized medicine in gynecologic cancer: fact or fiction? Obstet Gynecol Clin N Am 46(1):155–163
Dierickx A, Göker M, Braems G, Tummers P, Van den Broecke R (2016) Mesonephric adenocarcinoma of the cervix: case report and literature review. Gynecol Oncol Rep 17:7–11
Ervine A, Leung S, Gilks CB, McCluggage WG (2014) Thyroid transcription factor-1 (TTF-1) immunoreactivity is an adverse prognostic factor in endometrioid adenocarcinoma of the uterine corpus. Histopathology 64(6):840–846
Fregnani JH, Soares FA, Novik PR, Lopes A, Latorre MR (2008) Comparison of biological behavior between early-stage adenocarcinoma and squamous cell carcinoma of the uterine cervix. Eur J Obstet Gynecol Reprod Biol 136(2):215–223
Howitt BE, Nucci MR (2018) Mesonephric proliferations of the female genital tract. Pathology 50(2):141–150
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67–73
Kim SS, Nam JH, Kim GE, Choi YD, Choi C, Park CS (2016) Mesonephric adenocarcinoma of the uterine corpus: a case report and diagnostic pitfall. Int J Surg Pathol 24(2):153–158.
Kolin DL, Costigan DC, Dong F, Nucci MR, Howitt BE (2019) A combined morphologic and molecular approach to retrospectively identify KRAS-mutated mesonephric-like adenocarcinomas of the endometrium. Am J Surg Pathol 43(3):389–398
Labi FL, Evangelista S, Di Miscia A, Stentella P (2008) FIGO Stage I endometrial carcinoma: evaluation of lung metastases and follow-up. Eur J Gynaecol Oncol 29(1):65–66
Malpica A, Euscher ED, Hecht JL, Ali-Fehmi R, Quick CM, Singh N, Horn LC, Alvarado-Cabrero I, Matias-Guiu X, Hirschowitz L, Duggan M, Ordi J, Parkash V, Mikami Y, Ruhul Quddus M, Zaino R, Staebler A, Zaloudek C, McCluggage WG, Oliva E (2019) Endometrial carcinoma, grossing and processing issues: recommendations of the international society of gynecologic pathologists. Int J Gynecol Pathol 38(Suppl 1):S9–S24
Marquette A, Moerman P, Vergote I, Amant F (2006) Second case of uterine mesonephric adenocarcinoma. Int J Gynecol Cancer 16(3):1450–1454
McFarland M, Quick CM, McCluggage WG (2016) Hormone receptor-negative, thyroid transcription factor 1-positive uterine and ovarian adenocarcinomas: report of a series of mesonephric-like adenocarcinomas. Histopathology 68(7):1013–1020
Mirkovic J, McFarland M, Garcia E, Sholl LM, Lindeman N, MacConaill L, Dong F, Hirsch M, Nucci MR, Quick CM, Crum CP, McCluggage WG, Howitt BE (2018) Targeted genomic profiling reveals recurrent KRAS mutations in mesonephric-like adenocarcinomas of the female genital tract. Am J Surg Pathol 42(2):227–233
Montagut C, Mármol M, Rey V, Ordi J, Pahissa J, Rovirosa A, Gascón P, Mellado B (2003) Activity of chemotherapy with carboplatin plus paclitaxel in a recurrent mesonephric adenocarcinoma of the uterine corpus. Gynecol Oncol 90(2):458–461
Murali R, Grisham RN, Soslow RA (2018) The roles of pathology in targeted therapy of women with gynecologic cancers. Gynecol Oncol 148(1):213–221
Na K, Kim HS (2019) Clinicopathologic and molecular characteristics of mesonephric adenocarcinoma arising from the uterine body. Am J Surg Pathol 43(1):12–25
Ordi J, Nogales FF, Palacin A, Márquez M, Pahisa J, Vanrell JA, Cardesa A (2001) Mesonephric adenocarcinoma of the uterine corpus: CD10 expression as evidence of mesonephric differentiation. Am J Surg Pathol 25(12):1540–1545
Patel V, Kipp B, Schoolmeester JK (2019) Corded and hyalinized mesonephric-like adenocarcinoma of the uterine corpus: report of a case mimicking endometrioid carcinoma. Hum Pathol 86:243–248
Pors J, Cheng A, Leo JM, Kinloch MA, Gilks B, Hoang L (2018) A comparison of GATA3, TTF1, CD10, and calretinin in identifying mesonephric and mesonephric-like carcinomas of the gynecologic tract. Am J Surg Pathol 42(12):1596–1606
Pors J, Ho J, Prentice L, Thompson E, Cochrane D, Gibbard E, Huntsman D, Gilks B, Hoang LN (2019) c-KIT analysis and targeted molecular sequencing of mesonephric carcinomas of the female genital tract. Am J Surg Pathol. https://doi.org/10.1097/PAS.0000000000001403
Proctor L, Pradhan M, Leung S, Cheng A, Lee CH, Soslow RA, Gilks CB, Talhouk A, McAlpine JM, Danielsen HE, Hoang LN (2017) Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer. Gynecol Oncol 146(3):596–602
Sorosky JI (2008) Endometrial cancer. Obstet Gynecol 111(2 Pt 1):436–447
Soslow RA, Tornos C, Park KJ, Malpica A, Matias-Guiu X, Oliva E, Parkash V, Carlson J, McCluggage WG, Gilks CB (2019) Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the international society of gynecological pathologists. Int J Gynecol Pathol 38(Suppl 1):S64–S74
Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN (2015) A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 113(2):299–310
Wani Y, Notohara K, Tsukayama C (2008) Mesonephric adenocarcinoma of the uterine corpus: a case report and review of the literature. Int J Gynecol Pathol 27(3):346–352
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IEM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363(16):1532–1543
Wu H, Zhang L, Cao W, Hu Y, Liu Y (2014) Mesonephric adenocarcinoma of the uterine corpus. Int J Clin Exp Pathol 7(10):7012–7019 (eCollection 2014)
Yamamoto S, Sakai Y (2019) Pulmonary metastasis of mesonephric-like adenocarcinoma arising from the uterine body: a striking mimicry of follicular thyroid carcinoma. Histopathology 74(4):651–653
Yamamoto Y, Akagi A, Izumi K, Kishi Y (1995) Carcinosarcoma of the uterine body of mesonephric origin. Pathol Int 45(4):303–309
Yano M, Shintani D, Katoh T, Hamada M, Ito K, Kozawa E, Hasegawa K, Yasuda M (2019) Coexistence of endometrial mesonephric-like adenocarcinoma and endometrioid carcinoma suggests a Müllerian duct lineage: a case report. Diagn Pathol 14(1):54
Zhang L, Cai Z, Ambelil M, Conyers J, Zhu H (2019) Mesonephric adenocarcinoma of the uterine corpus: report of 2 cases and review of the literature. Int J Gynecol Pathol 38(3):224–229
Funding
The authors declare that there was no funding of the study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Horn, LC., Höhn, A.K., Krücken, I. et al. Mesonephric-like adenocarcinomas of the uterine corpus: report of a case series and review of the literature indicating poor prognosis for this subtype of endometrial adenocarcinoma. J Cancer Res Clin Oncol 146, 971–983 (2020). https://doi.org/10.1007/s00432-019-03123-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-019-03123-7